Waldenström's Macroglobulinaemia: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up

Ann Oncol. 2018 Oct 1;29(Suppl 4):iv41-iv50. doi: 10.1093/annonc/mdy146.

Publication types

  • Practice Guideline

MeSH terms

  • Aftercare / methods
  • Aftercare / standards
  • Age of Onset
  • Antineoplastic Combined Chemotherapy Protocols / standards
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Asymptomatic Diseases / therapy
  • Bone Marrow / pathology
  • Europe
  • Humans
  • Incidence
  • Medical Oncology / methods
  • Medical Oncology / standards*
  • Myeloid Differentiation Factor 88 / genetics
  • Neoplasm Recurrence, Local / diagnosis
  • Neoplasm Recurrence, Local / epidemiology
  • Neoplasm Recurrence, Local / pathology
  • Neoplasm Recurrence, Local / therapy*
  • Neoplasm Staging
  • Plasmapheresis / methods
  • Plasmapheresis / standards
  • Precision Medicine / methods
  • Precision Medicine / standards*
  • Receptors, CXCR4 / genetics
  • Societies, Medical / standards*
  • Stem Cell Transplantation / methods
  • Stem Cell Transplantation / standards
  • Survivorship
  • Transplantation, Autologous / methods
  • Transplantation, Autologous / standards
  • Treatment Outcome
  • Waldenstrom Macroglobulinemia / diagnosis
  • Waldenstrom Macroglobulinemia / epidemiology
  • Waldenstrom Macroglobulinemia / pathology
  • Waldenstrom Macroglobulinemia / therapy*

Substances

  • CXCR4 protein, human
  • MYD88 protein, human
  • Myeloid Differentiation Factor 88
  • Receptors, CXCR4